Skip to main content
SpringerLink
Log in

Analysis of the principles underlying chemo-immunotherapy of mouse tumours

I. Treatment with cyclophosphamide followed by Corynebacterium parvum

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

A CBA mouse fibrosarcoma (M4) growing as a solid tumour was treated with a single high dose (200 mg/kg) of cyclophosphamide (CY) followed by C. parvum (CP) immunotherapy. The optimal time for the administration of both nonspecific (CP IV) and active specific (SC CP-irradiated tumour cell mixtures) immunotherapy after CY was 4 days, compared with 1, 8, or 12 days. Optimal combinations of CY and CP were ‘synergistic’ in that they provided a stronger antitumour effect than the sum of the individual effects of the two agents. In keeping with the finding that a 4-day interval between CY and CP was better than only 1 day, studies in normal mice show that when CP is given early during the suppressive phase of CY the onset of both specific and nonspecific antitumour effects are delayed. CY increased the susceptibility of mice to the toxic effects of a subsequent high systemic dose of CP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bach, J.-F.: The mode of action of immunosuppressive agents. In: Frontiers of biology, Vol. 41, p. 173. Amsterdam: North-Holland 1973

    Google Scholar 

  • Bomford, R.: Active specific immunotherapy of mouse methylcholanthrene-induced tumours with Corynebacterium parvum and irradiated tumour cells. Br. J. Cancer 32, 551 (1975)

    Google Scholar 

  • Currie, G. A., Bagshawe, K. D.: Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcoma. Br. Med. J. 1970 1, 541

    Google Scholar 

  • Fisher, B., Wolmark, N., Rubin, H., Saffer, E.: Further observations on the inhibition of tumour growth by Corynebacterium parvum with cyclophosphamide. I. Variation in administration of both agents. J. Natl. Cancer Inst. 55, 1147 (1975)

    Google Scholar 

  • Fisher, B., Rubin, H., Saffer, E., Wolmark, N.: The effect of Corynebacterium parvum in combination with 5-fluorouracil, l-phenylalanine mustard or methotrexate on the inhibition of tumour growth. Cancer Res. 36, 2714 (1976)

    CAS  PubMed  Google Scholar 

  • Hattori, T., Yamagata, S.: Combined treatment with anaerobic Corynebacterium liquefaciens and chemotherapeutics against solid tumour in mice. Gann 68, 115 (1977)

    Google Scholar 

  • Milas, L., Scott, M. T.: Antitumour activity of Corynebacterium parvum. Adv. Cancer Res. 26, 257 (1978)

    Google Scholar 

  • Olivotto, M., Bomford, R.: In vitro inhibition of tumour cell growth and DNA synthesis by peritoneal and lung macrophages from mice injected with Corynebacterium parvum. Int. J. Cancer 13, 478 (1974)

    Google Scholar 

  • Pearson, J. W., Chirigos, M. A., Chaparas, S. D., Sher, N. A.: Combined drug and immunostimulation therapy against a syngeneic murine leukaemia. J. Natl. Cancer Inst. 52, 463 (1974)

    Google Scholar 

  • Pearson, J. W., Perk, K., Chirigos, M. A., Pryor, J. W., Fuhrman, F. S.: Histological and combined chemoimmunostimulation therapy studies against a murine leukaemia. Int. J. Cancer 16, 142 (1975)

    Google Scholar 

  • Purnell, D. M., Bartlett, G. L., Kreider, J. W., Biro, T. G.: Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma. Cancer Res. 37, 1137 (1977)

    Google Scholar 

  • Sansing, W. A., Killion, J. J., Kollmorgen, G. M.: Evaluation of time and dose in treating mammary adenocarcinoma with immunostimulants. Cancer Immunol. Immunother. 2, 63 (1977)

    Google Scholar 

  • Scott, M. T.: Corynebacterium parvum as a therapeutic antitumour agent in mice. 1. Systemic effects from intravenous injection. J. Natl. Cancer Inst. 53, 855 (1974)

    CAS  PubMed  Google Scholar 

  • Scott, M. T.: Potentiation of the tumor-specific immune response by Corynebacterium parvum. J. Natl. Cancer Inst. 55, 65 (1975)

    Google Scholar 

  • Scott, M. T.: Conditions favouring the selection of either specific or non-specific C. parvum-mediated systemic antitumour immunity in mice. Dev. Biol. Stand. 38, 273 (1978)

    Google Scholar 

  • Scott, M. T.: Analyses of the principles underlying chemo-immunotherapy of mouse tumours. II. Treatment with Corynebacterium parvum followed by cyclophosphamide. Cancer Immunol. Immunother. (in press, 1979)

  • Scott, M. T., Milas, L.: The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumour activity. Cancer Res. 37, 1673 (1977)

    Google Scholar 

  • Scott, M. T., Warner, S. L.: The accumulated effects of repeated systemic or local injections of low doses of Corynebacterium parvum in mice. Cancer Res. 36, 1335 (1976)

    Google Scholar 

  • Stadecker, M. J., Calderon, J., Karnovsky, M. L., Unanue, E. R.: Synthesis and release of thymidine by macrophages. J. Immunol. 119, 1738 (1977)

    Google Scholar 

  • Tagliabue, A., Polentarutti, N., Vecchi, A., Mantovani, A., Spreafico, F.: Combination chemo-immunotherapy with adriamycin in experimental tumour systems. Eur. J. Cancer 13, 657 (1977)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Immunobiology, The Wellcome Research Laboratories, BR3 3BS, Beckenham, Kent, England

    M. T. Scott

Authors
  1. M. T. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, M.T. Analysis of the principles underlying chemo-immunotherapy of mouse tumours. Cancer Immunol Immunother 6, 107–112 (1979). https://doi.org/10.1007/BF00200139

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00200139

Keywords

Search

Navigation